Literature DB >> 12659634

Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1.

David Berry1, Zachary Shriver, Barbara Natke, Chi-Pong Kwan, Ganesh Venkataraman, Ram Sasisekharan.   

Abstract

Fibroblast growth factor (FGF) signalling is involved in a wide range of important biological activities with differential effects in various cell types. The activity of FGF is modulated by heparin/heparan sulphate-like glycosaminoglycans (HSGAGs), found both in the extracellular matrix and on the cell surface. HSGAGs affect FGF signalling by interacting with both the growth factor and the FGF receptor (FGFR). In this study we sought to investigate whether HSGAGs at the cell surface of bovine aortic endothelial cells (BAEC) and smooth muscle cells (SMC) can differentially modulate FGF signalling in these cell types and modulate their differential response to FGF. We find that SMC and BAEC express the same FGFR isoforms and bind FGF2 with equal affinity at the cell surface, yet FGF has a markedly higher proliferative effect on SMC than on BAEC. Isolated HSGAGs from these two cell types were found to elicit distinct patterns of proliferation in chlorate-treated cells. Furthermore, examination of focal sequences reveals that HSGAGs from SMC, but not those from BAEC, retain the sulphation pattern necessary to induce FGF2 activity. As such, the differences in FGF2-mediated proliferation can be explained by the distinct cell surface HSGAGs of the two cell types. We conclude that the focal sequences of cell surface HSGAGs from SMC and BAEC govern, at least in part, the differential activity of FGF2 on these two cell types.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12659634      PMCID: PMC1223466          DOI: 10.1042/BJ20021760

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Identification of glypican as a dual modulator of the biological activity of fibroblast growth factors.

Authors:  D Bonneh-Barkay; M Shlissel; B Berman; E Shaoul; A Admon; I Vlodavsky; D J Carey; V K Asundi; R Reich-Slotky; D Ron
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

2.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

3.  Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.

Authors:  T Ashikaga; S J Strada; W J Thompson
Journal:  Biochem Pharmacol       Date:  1997-11-15       Impact factor: 5.858

4.  Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ.

Authors:  Z Chang; K Meyer; A C Rapraeger; A Friedl
Journal:  FASEB J       Date:  2000-01       Impact factor: 5.191

5.  Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action.

Authors:  S Clasper; S Vekemans; M Fiore; M Plebanski; P Wordsworth; G David; D G Jackson
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

6.  Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis.

Authors:  S Björnsson
Journal:  Anal Biochem       Date:  1998-02-15       Impact factor: 3.365

7.  The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates.

Authors:  V Nurcombe; C E Smart; H Chipperfield; S M Cool; B Boilly; H Hondermarck
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

8.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

9.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.

Authors:  E R Edelman; D H Adams; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

10.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation.

Authors:  O Saksela; D Moscatelli; A Sommer; D B Rifkin
Journal:  J Cell Biol       Date:  1988-08       Impact factor: 10.539

View more
  6 in total

1.  Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells.

Authors:  Gui Su; Kristy Meyer; Chilkunda D Nandini; Dianhua Qiao; Shahriar Salamat; Andreas Friedl
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 2.  Engineering antiphagocytic biomimetic drug carriers.

Authors:  Alicia Sawdon; Ching-An Peng
Journal:  Ther Deliv       Date:  2013-07

3.  The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling.

Authors:  Megan S Lord; Christine Y Chuang; James Melrose; Michael J Davies; Renato V Iozzo; John M Whitelock
Journal:  Matrix Biol       Date:  2014-02-06       Impact factor: 11.583

4.  FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.

Authors:  Jane Reiland; Doty Kempf; Madhuchhanda Roy; Yvonne Denkins; Dario Marchetti
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

5.  Comparative Analysis of the Expression of Chondroitin Sulfate Subtypes and Their Inhibitory Effect on Axonal Growth in the Embryonic, Adult, and Injured Rat Brains.

Authors:  Moon Hang Kim; So Ra Park; Byung Hyune Choi
Journal:  Tissue Eng Regen Med       Date:  2020-09-16       Impact factor: 4.169

6.  Angiogenic efficacy of Heparin on chick chorioallantoic membrane.

Authors:  Reji Bhuvanendran Rema; Karthick Rajendran; Malathi Ragunathan
Journal:  Vasc Cell       Date:  2012-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.